Inflammatory mediators in sepsis: Cytokines, chemokines, adhesion molecules and gases

Journal of Organ Dysfunction

Volumn 2, Issue 2, 2006, Pages 80-92

  Devi Ramnath, Raina ^a   Weing, Siaw ^a   He, Min ^a   Sun, Jia ^a   Zhang, Huili ^a   Singh Bawa, Manmish ^a   Bhatia, Madhav ^a  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

Adhesion molecules; Chemokines; Cytokines; Gaseous mediators; Sepsis

Indexed keywords

CELL ADHESION MOLECULE; CHEMOKINE; CYTOKINE; ENZYME INHIBITOR; HIGH MOBILITY GROUP B1 PROTEIN; HYDROGEN SULFIDE; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; INTERLEUKIN 6; NITRIC OXIDE; PROPARGYLGLYCINE; PROTEIN ANTIBODY; SELECTIN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA RECEPTOR; VASCULAR CELL ADHESION MOLECULE 1;

DEATH; HUMAN; INFECTION; INFLAMMATION; LEUKOCYTE MIGRATION; MULTIPLE ORGAN FAILURE; NEUTROPHIL; NONHUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SEPSIS; SHOCK;

EID: 33745112931     PISSN: 17471060     EISSN: 17471079     Source Type: Journal    
DOI: 10.1080/17471060500435662     Document Type: Review

References (141)

1. Alberti C, Brun-Buison C, Burchardi H, Martin C, Goodman S, Artigas A, et al. Epidemiology of sepsis and infection in ICU patients from international multicenter cohort study. Intensive Care Med 2002;28:108-21.
2. Martin GS, Mannino DM, Eaton S, Moss M. The epidemiology of sepsis in the United States from 1979-2000. N Engl J Med 2003;348:1546-54.
3. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky JR. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001;29:1303-10.
4. Opal SM, Cross AS. Clinical trials for sepsis: past failures and future hopes. Infect Dis Clin North Am 1999;13:285-98.
5. Modlin RL, Brightbill HD, Godowski PJ. The toll of innate immunity on microbial pathogens. N Engl J Med 1999;340:1834-5.
6. Underhill DM, Ozinsky A. Toll-like receptors: key mediators of microbe detection. Curr Opin Immunol 2002;14:103-10.
7. Underhill DM. Toll-like receptors: networking for success. Eur J Immunol 2003;33:1767-75.
8. Vasselon T, Detmers PA. Toll receptors: a central element in innate immune responses. Infect Immun 2002;70:1033-41.
9. Bone RC. The pathogenesis of sepsis. Ann Intern Med 1991;115:457-69.
10. Jacobi J. Pathophysiology of sepsis. Am J Health Syst Pharm 2002;59(Suppl 1):S3-8.
11. Evans TJ. The role of macrophages in septic shock. Immunobiology 1996;195:655-9.
12. Bone RC, Grodzin CJ, Balk RA. Sepsis: a new hypothesis for pathogenesis of the disease process. Chest 1997;112:235-43.
13. Dhainaut JP, Lambertus GT, Park G. Septic shock. London: WB Saunders; 2000.
14. Fink MP, Heard SO. Laboratory models of sepsis and septic shock. J Surg Res 1990;49:186-96.
15. Wichterman KA, Baue AE, Chaudry IH. Sepsis and septic shock - a review of laboratory models and a proposal. J Surg Res 1980;29:189-201.
16. Remick DG, Newcomb DE, Bolgos GL, Call DR. Comparison of the mortality and inflammatory response of two models of sepsis: lipopolysaccharide vs. cecal ligation and puncture. Shock 2000;13:110-6.
17. Koch E, Klaas CA, Rungeler P, Castro V, Mora G, Vichnewski W, et al. Inhibition of inflammatory cytokine production and lymphocyte proliferation by structurally different sesquiterpene lactones correlates with effect on activation of NF-kappaB. Biochem Pharmacol 2001;62:795-801.
18. Siebenlist U, Franzoso G, Brown K. Structure, regulation, and function of NF-kB. Annu Rev Cell Biol 1994;10:405-55.
19. Blackwell TS, Christman JW. Sepsis and cytokines: current status. Br J Anaesth 1996;77:110-7.
20. Bhatia M, Moochhala S. Role of inflammatory mediators in the pathophysiology of acute respiratory distress syndrome. J Pathol 2004;202:145-56.
21. Putensen C, Wrigge H. Ventilator-associated systemic inflammation in acute lung injury. Intensive Care Med 2000;26:1411-3.
22. Cohen J. The immunopathogenesis of sepsis. Nature 2002;420:885-91.
23. Walley KR, Lukacs NW, Standiford TJ, Strieter RM, Kunkel SL. Balance of inflammatory cytokines related to severity and mortality of murine sepsis. Infect Immun 1996;64:4733-8.
24. Beutler B, Milsark IW, Cerami AC. Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin. Science 1985;229:869-71.
25. Mathison JC, Wolfson E, Ulevitch RJ. Participation of tumor necrosis factor in the mediation of gram negative bacterial lipopolysaccharide-induced injury in rabbits. J Clin Invest 1988;81:1925-37.
26. Tracey KJ, Cerami A. Tumor necrosis factor: a pleiotropic cytokine and therapeutic target. Annu Rev Med 1994;45:491-503.
27. Beutler B, Grau GE. Tumor necrosis factor in the pathogenesis of infectious diseases. Crit Care Med 1993;21:S423-35.
28. Gogos CA, Drosou E, Bassaris HP, Skoutelis A. Pro-versus anti-inflammatory cytokine profile in patients with severe sepsis: a marker for prognosis and future therapeutic options. J Infect Dis 2000;181:176-80.
29. Fong Y, Tracey KJ, Moldawer LL, Hesse DG, Manogue KB, Kenney JS, et al. Antibodies to cachectin/tumor necrosis factor reduce interleukin 1 beta and interleukin 6 appearance during lethal bacteremia. J Exp Med 1989;170:1627-33.
30. Redl H, Schlag G, Ceska M, Davies J, Buurman WA. Interleukin-8 release in baboon septicemia is partially dependent on tumor necrosis factor. J Infect Dis 1993;167:1464-6.
31. Eskandari MK, Bolgos G, Miller C, Nguyen DT, DeForge LE, Remick DG. Anti-tumor necrosis factor antibody therapy fails to prevent lethality after cecal ligation and puncture or endotoxemia. J Immunol 1992;148:2724-30.
32. Remick D, Manohar P, Bolgos G, Rodriguez J, Moldawer L, Wollenberg G. Blockade of tumor necrosis factor reduces lipopolysaccharide lethality, but not the lethality of cecal ligation and puncture. Shock 1995;4:89-95.
33. Calandra T, Baumgartner JD, Grau GE, Wu MM, Lambert PH, Schellekens J, et al. Prognostic values of tumor necrosis factor/cachectin, interleukin-1, interferon-alpha, and interferon-gamma in the serum of patients with septic shock. Swiss-Dutch J5 Immunoglobulin Study Group. J Infect Dis 1990;161:982-7.
34. Marks JD, Marks CB, Luce JM, Montgomery AB, Turner J, Metz CA, et al. Plasma tumor necrosis factor in patients with septic shock. Mortality rate, incidence of adult respiratory distress syndrome, and effects of methylprednisolone administration. Am Rev Respir Dis 1990;141:94-7.
35. Raza A. Anti-TNF therapies in rheumatoid arthritis, Crohn's disease, sepsis, and myelodysplastic syndromes. Microsc Res Tech 2000;50:229-35.
36. Abraham E, Wunderink R, Silverman H, Perl TM, Nasraway S, Levy H, et al. Efficacy and safety of monoclonal antibody to human tumor necrosis factor alpha in patients with sepsis syndrome. A randomized, controlled, double-blind, multicenter clinical trial. TNF-alpha MAb Sepsis Study Group. JAMA 1995;273:934-41.
37. Beutler BA, Milsark IW, Cerami A. Cachectin/tumor necrosis factor: production, distribution, and metabolic fate in vivo. J Immunol 1985;135:3972-7.
38. Wang H, Bloom O, Zhang M, Vishnubhakat JM, Ombrellino M, Che J, et al. HMG-1 as a late mediator of endotoxin lethality in mice. Science 1999;285:248-51.
39. Wang H, Yang H, Czura CJ, Sama AE, Tracey KJ. HMGB1 as a late mediator of lethal systemic inflammation. Am J Respir Crit Care Med 2001;164:1768-73.
40. Wang H, Czura CJ, Tracey KJ. HMGB1. In: Thomson A, Lotze MT, editors. The cytokine handbook. London: Academic Press; 2003; p. 913-23.
41. Johns EW. History, definitions and problems. In: Johns EW, editor. The HMG chromosomal proteins. London: Academic Press; 1982; p. 1-8.
42. Bustin M. Regulation of DNA-dependent activities by the functional motifs of the high-mobility-group chromosomal proteins. Mol Cell Biol 1999;19:5237-46.
43. Hori O, Brett J, Slattery T, Cao R, Zhang J, Chen JX, et al. The receptor for advanced glycation end products (RAGE) is a cellular binding site for amphoterin. Mediation of neurite outgrowth and co-expression of rage and amphoterin in the developing nervous system. J Biol Chem 1995;270:25752-61.
44. Sousa MM, Yan SD, Stern D, Saraiva MJ. Interaction of the receptor for advanced glycation end products (RAGE) with transthyretin triggers nuclear transcription factor kB (NF-kB) activation. Lab Invest 2000;80:1101-10.
45. Thornalley PJ. Cell activation by glycated proteins. AGE receptors, receptor recognition factors and functional classification of AGEs. Cell Mol Biol (Noisy-le-grand) 1998;44:1013-23.
46. Sappington PL, Yang R, Yang H, Tracey KJ, Delude RL, Fink MP. HMGB1 B box increases the permeability of Caco-2 enterocytic monolayers and causes derangements in intestinal barrier function in mice. Gastroenterology 2002;123:790-802.
47. Fiuza C, Bustin M, Talwar S, Tropea M, Gerstenberger E, Shelhamer JH, et al. Inflammation-promoting activity of HMGB1 on human microvascular endothelial cells. Blood 2002;101:2652-60.
48. Riedemann NC, Guo RF, Ward PA. Novel strategies for the treatment of sepsis. Nat Med 2003;9:517-24.
49. Yang H, Ochani M, Li J, Qiang X, Tanovic M, Harris HE, et al. Reversing established sepsis with antagonists of endogenous HMGB1. Proc Natl Acad Sci U S A 2004;101:296-301.
50. Wang H, Bloom O, Zhang M, Vishnubhakat JM, Ombrellino M, Che J, et al. HMG-1 as a late mediator of endotoxin lethality in mice. Science 1999;285:248-51.
51. Wang H, Yang H, Czura CJ, Sama AE, Tracey KJ. HMGB1 as a late mediator of lethal systemic inflammation. Am J Respir Crit Care Med 2001;164:1768-73.
52. Ulloa L, Ochani M, Yang H, Tanovic M, Halperin D, Yang R, et al. Ethyl pyruvate prevents lethality in mice with established lethal sepsis and systemic inflammation. Proc Natl Acad Sci U S A 2002;99:12351-6.
53. Wang H, Yang H, Tracey KJ. Extracellular role of HMGB1 in inflammation and sepsis. J Intern Med 2004;255:320-31.
54. Okusawa S, Gelfland JA, Ikejima T, Connolly RJ, Dinarello CA. Interleukin 1 induces a shock-like state in rabbits. Synergism with tumor necrosis factor and the effect of cyclooxygenase inhibition. J Clin Invest 1988;81:1162-72.
55. Tracey JK, Beutler B, Lowry SF, Merryweather J, Wolpe S, Milsark IW, et al. Shock and tissue injury induced by recombinant human cachectin. Science 1986;234:470-4.
56. Bhatia M, Brady M, Shokuhi S, Christmas S, Neoptolemos JP, Slavin J. Inflammatory mediators in acute pancreatitis. J Pathol 2000;190:117-25.
57. Bhatia M, Neoptolemos JP, Slavin J. Inflammatory mediators as therapeutic targets in acute pancreatitis. Curr Opin Invest Drugs 2001;2:496-501.
58. Nijsten NWN, Hack CE, Helle M, Ten Duis HJ, Klassen HJ, Aarden LA. Interleukin-6 and its relation to the humoral immune response and clinical parameters in burned patients. Surgery 1991;109:761-7.
59. Borrelli E, Roux-Lombard P, Grau GE, Girardin E, Ricou B, Dayer J, et al. Plasma concentrations of cytokines, their soluble receptors, and antioxidant vitamins can predict the development of multiple organ failure in patients at risk. Crit Care Med 1996;24:392-7.
60. Geiger T, Andus T, Klapproth J, Hirano T, Kishimoto T, Heinrich PC. Induction of rat acute-phase proteins by interleukin 6 in vivo. Eur J Immunol 1988;18:717-21.
61. Castell JV, Gomez-Lechon MJ, David M, Andus T, Geiger T, Trullenque R, et al. Interleukin-6 is the major regulator of acute phase protein synthesis in adult human hepatocytes. FEBS Lett 1989;242:237-9.
62. Dinarello CA. Proinflammatory and anti-inflammatory cytokines as mediators in the pathogenesis of septic shock. Chest 1997;112:321S-9S.
63. Kasama T, Strieter RM, Lukacs NW, Burdick MD, Kunkel SL. Regulation of neutrophil-derived chemokine expression by IL-10. J Immunol 1994;152:3559-69.
64. Howard M, O'Garra A, Ishida H, de Wall Malefyt R, de Vries J. Biological properties of interleukin 10. J Clin Immunol 1992;12:239-47.
65. Howard M, Muchamuel T, Andrade S, Menon S. Interleukin 10 protects mice from lethal endotoxemia. J Exp Med 1993;177:1205-8.
66. Van der Poll T, Jansen PM, Montegut WJ, Braxton CC, Calvano SE, Stackpole SE. Effects of IL-10 on systemic inflammatory responses during sublethal primate endotoxemia. J Immunol 1997;158:1971-5.
67. Ertel W, Scholl FA, Gallati H, Bonaccio M, Schildberg FW, Trentz O. Increased release of soluble tumor necrosis factor receptors into blood during clinical sepsis. Arch Surg 1994;129:1330-7.
68. Arend WP, Malyak M, Guthridge CJ, Gabay C. Interleukin-1 receptor antagonist: role in biology. Annu Rev Immunol 1998;16:27-55.
69. Ohlsson K, Bjork P, Bergenfeldt M, Hageman R, Thompson RC. Interleukin-1 receptor antagonist reduces mortality from endotoxin shock. Nature 1990;348:550-2.
70. Fischer E, Marano MA, Van Zee KJ, Rock CS, Hawes AS, Thompson WA, et al. Interleukin-1 receptor blockade improves survival and hemodynamic performance in Escherichia coli septic shock, but fails to alter host responses to sublethal endotoxemia. J Clin Invest 1992;89:1551-7.
71. Goldie AS, Fearon KC, Ross JA, Barclay GR, Jackson RE, Grant IS, et al. Natural cytokine antagonists and endogenous antiendotoxin core antibodies in sepsis syndrome. The Sepsis Intervention Group. JAMA 1995;274:172-7.
72. Proudfoot AE. Chemokine receptors: multifaceted therapeutic targets. Nat Rev Immunol 2002;2:106-15.
73. Rollins BJ. Chemokines. Blood 1997;90:909-28.
74. Luster AD. Chemokines - chemotactic cytokines that mediate inflammation. N Engl J Med 1998;338:436-45.
75. Schinkel S, Schinkel C, Pollard V, Garofallo R, Heberle H, Reisner P, et al. Effects of endotoxin on serum chemokines in man. Eur J Med Res 2005;10:76-80.
76. Chishti AD, Shenton BK, Kirby JA, Baudouin SV. Neutrophil chemotaxis and receptor expression in clinical septic shock. Intensive Care Med 2004;30:605-11.
77. Lomas-Neira JL, Chung CS, Grutkoski PS, Miller EJ, Ayala A. CXCR2 inhibition suppresses hemorrhage-induced priming for acute lung injury in mice. J Leukoc Biol 2004;76:58-64.
78. Ness TL, Hogaboam CM, Strieter RM, Kunkel SL. Immunomodulatory role of CXCR2 during experimental septic peritonitis. J Immunol 2003;171:3775-84.
79. Kaneider NC, Agarwal A, Leger AJ, Kuliopulos A. Reversing systemic inflammatory response syndrome with chemokine receptor pepducins. Nat Med 2005;11:661-5.
80. Ness TL, Carpenter KJ, Ewing JL, Gerard CJ, Hogaboam CM, Kunkel SL. CCR1 and CC chemokine ligand 5 interactions exacerbate innate immune responses during sepsis. J Immunol 2004;173:6938-48.
81. Takahashi H, Tashiro T, Miyazaki M, Kobayashi M, Pollard RB, Suzuki F. An essential role of macrophage inflammatory protein 1(/CCL3 on the expression of host's innate immunities against infectious complications. J Leukoc Biol 2002;72:1190-7.
82. Steinhauser ML, Hogaboam CM, Matsukawa A, Lukacs NW, Strieter RM, Kunkel SL. Chemokine C10 promotes disease resolution and survival in an experimental model of bacterial sepsis. Infect Immun 2000;68:6108-14.
83. Speyer CL, Gao H, Rancilio NJ, Neff TA, Huffnagle GB, Sarma JV, et al. Novel chemokine responsiveness and mobilization of neutrophils during sepsis. Am J Pathol 2004;165:2187-96.
84. Daly C, Rollins BJ. Monocyte chemoattractant protein-1 (CCL2) in inflammatory disease and adaptive immunity: therapeutic opportunities and controversies. Microcirculation 2003;10:247-57.
85. Rose CE Jr, Sung SS, Fu SM. Significant involvement of CCL2 (MCP-1) in inflammatory disorders of the lung. Microcirculation 2003;10:273-88.
86. Matsukawa A, Hogaboam CM, Lukacs NW, Lincoln PM, Strieter RM, Kunkel SL. Endogenous MCP-1 influences systemic cytokine balance in a murine model of acute septic peritonitis. Exp Mol Pathol 2000;68:77-84.
87. Feterowski C, Mack M, Weighardt H, Bartsch B, Kaiser-Moore S, Holzmann B. CC chemokine receptor 2 regulates leukocyte recruitment and IL-10 production during acute polymicrobial sepsis. Eur J Immunol 2004;34:3664-73.
88. Chvatchko Y, Hoogewerf AJ, Meyer A, Alouani S, Juillard P, Buser R, et al. A key role for CC chemokine receptor 4 in lipopolysaccharide-induced endotoxic shock. J Exp Med 2000;191:1755-64.
89. Vallet B. Bench-to-bedside review: endothelial cell dysfunction in severe sepsis: a role in organ dysfunction? Crit Care 2003;7:130-8.
90. Tedder TF, Steeber DA, Chen A, Engel P. The selectins: vascular adhesion molecules. FASEB J 1995;9:866-73.
91. Collins T, Read MA, Neish AS, Whitley MZ, Thanos D, Maniatis T. Transcriptional regulation of endothelial cell adhesion molecules: NF-kappa B and cytokine-inducible enhancers. FASEB J 1995;9:899-909.
92. Carlos TM, Harlan JM. Leukocyte-endothelial adhesion molecules. Blood 1994;84:2068-101.
93. Malhotra R, Bird MI. L-Selectin - a signalling receptor for lipopolysaccharide. Chem Biol 1997;4:543-7.
94. Tedder TF, Steeber DA, Pizcueta P. L-selectin-deficient mice have impaired leukocyte recruitment into inflammatory sites. J Exp Med 1995;181:2259-64.
95. Donnelly SC, Haslett C, Dransfield I, Robertson CE, Carter DC, Ross JA, et al. Role of selectins in development of adult respiratory distress syndrome. Lancet 1994;344:215-9.
96. Malhotra R, Priest R, Foster MR, Bird MI. P-selectin binds to bacterial lipopolysaccharide. Eur J Immunol 1998;28:983-8.
97. Malhotra R, Priest R, Bird MI. Role for L-selectin in lipopolysaccharide-induced activation of neutrophils. Biochem J 1996;320:589-93.
98. Van de Stolpe A, van der Saag PT. Intercellular adhesion molecule-1. J Mol Med 1996;74:13-33.
99. Roebuck KA, Finnegan A. Regulation of intercellular adhesion molecule-1 (CD54) gene expression. J Leukoc Biol 1999;66:876-88.
100. Reinhart K, Bayer O, Brunkhorst F, Meisner M. @Markers of endothelial damage in organ dysfunction and sepsis. Crit Care Med 2002;30(5 Suppl):S302-12.
101. Whalen MJ, Doughty LA, Carlos TM, Wisniewski SR, Kochanek PM, Carcillo JA. Intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 are increased in the plasma of children with sepsis-induced multiple organ failure. Crit Care Med 2000;28:2600-7.
102. Laudes IJ, Guo RF, Riedemann NC, Speyer C, Craig R, Sarma JV, et al. Disturbed homeostasis of lung intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 during sepsis. Am J Pathol 2004;164:1435-45.
103. Xu H, Gonzalo JA, St Pierre Y, Williams IR, Kupper TS, Cotran RS, et al. Leukocytosis and resistance to septic shock in intercellular adhesion molecule 1-deficient mice. J Exp Med 1994;180:95-109.
104. Sade K, Schwartz D, Wolman Y, Schwartz I, Chernichovski T, Blum M, et al. Time course of lipopolysaccharide-induced nitric oxide synthase mRNA expression in rat glomeruli. J Lab Clin Med 1999;134:471-7.
105. Harada S, Imaki T, Chikada N, Naruse M, Demura H. Distinct distribution and time-course changes in neuronal nitric oxide synthase and inducible NOS in the paraventricular nucleus following lipopolysaccharide injection. Brain Res 1999;821:322-32.
106. Chen K, Inoue M, Okada A. Expression of inducible nitric oxide synthase mRNA in rat digestive tissues after endotoxin and its role in intestinal mucosal. Biochem Biophys Res Commun 1996;224:703-8.
107. Preiser JC, Zhang H, Vray B, Hrabak A, Vincent JL. Time course of inducible nitric oxide synthase activity following endotoxin administration in dogs. Nitric Oxide 2001;5:208-11.
108. Kengatharan KM, De Kimpe SJ, Thiemermann C. Role of nitric oxide in the circulatory failure and organ injury in a rodent model of gram-positive shock. Br J Pharmacol 1996;119:1411-21.
109. Shieh P, Zhou M, Ornan DA, Chaudry IH, Wang P. Upregulation of inducible nitric oxide synthase and nitric oxide occurs later than the onset of the hyperdynamic response during sepsis. Shock 2000;13:325-9.
110. Scott JA, Mehta S, Duggan M, Bihari A, McCormack DG. Functional inhibition of constitutive nitric oxide synthase in a rat model of sepsis. Am J Respir Crit Care Med 2002;165:1426-32.
111. Beasley D, Eldridge M. Interleukin-1 beta and tumor necrosis factor-alpha synergistically induce NO synthase in rat vascular smooth muscle cells. Am J Physiol 1994;266:R1197-203.
112. Cunha FQ, Assreuy J, Moss DW, Rees D, Leal LM, Moncada S, et al. Differential induction of nitric oxide synthase in various organs of the mouse during endotoxaemia: role of TNF-alpha and IL-1. Immunology 1994;81:211-5.
113. Gocan NC, Scott JA, Tyml K. Nitric oxide produced via neuronal NOS may impair vasodilatation in septic rat skeletal muscle. Am J Physiol Heart Circ Physiol 2000;278:H1480-9.
114. Salvemini D, Korbut R, Änggard E, Vane J. Immediate release of a nitric oxide-like factor from bovine aortic endothelial cells by Escherichia coli lipopolysaccharide. Proc Natl Acad Sci U S A 1990;87:2593-7.
115. Liu S, Adcock IM, Old RW, Barnes PJ, Evans TW. Lipopolysaccharide treatment in vivo induces widespread tissue expression of inducible nitric oxide synthase mRNA. Biochem Biophys Res Commun 1993;196:1208-13.
116. Kengatharan KM, De Kimpe S, Robson C, Foster SJ, Thiemermann C, et al. Mechanism of Gram-positive shock identification of peptidoglycan lipoteichoic acid moieties essential in the induction of nitric oxide synthase, shock, and multiple organ failure. J Exp Med 1998;188:305-15.
117. Thiemermann C, Vane JR. Inhibition of nitric oxide synthesis reduces the hypotension induced by bacterial lipopolysaccharide in the rat. Eur J Pharmacol 1990;182:591-5.
118. Kilbourn RG, Gross SS, Jubran A, Adams J, Griffith OW, Levi R, et al. N G-methyl- L-arginine inhibits tumor necrosis factor-induced hypotension: implications for the involvement of nitric oxide. Proc Natl Acad Sci U S A 1990;87:3629-32.
119. Wei XQ, Charles IG, Smith A, Ure J, Feng GJ, Huang FP, et al. Altered immune responses in mice lacking inducible nitric oxide synthase. Nature 1995;375:408-11.
120. Gunnett CA, Chu Y, Heistad DD, Loihl A, Faraci FM. Vascular effects of LPS in mice deficient in expression of the gene for inducible nitric oxide synthase. Am J Physiol 1998;275:H416-21.
121. Hollenberg SM, Piotrowski MJ, Parrillo JE. Nitric oxide synthase inhibition reverses arteriolar hyporesponsiveness to endothelin-1 in septic rats. Am J Physiol 1997;272:R969-74.
122. Hollenberg SM, Cunnion RE, Zimmerberg J. Nitric oxide synthase inhibition reverses arteriolar hyporesponsiveness to catecholamines in septic rats. Am J Physiol 1993;264:H660-3.
123. Flesch M, Kilter H, Cremers B, Laufs U, Sudkamp M, Ortmann M, et al. Effects of endotoxin on human myocardial contractility involvement of nitric oxide and peroxynitrite. J Am Coll Cardiol 1999;33:1062-70.
124. Nussler AK, Di Silvio M, Billiar TR, Hoffman RA, Geller DA, Selby R, et al. Stimulation of the nitric oxide synthase pathway in human hepatocytes by cytokines and endotoxin. J Exp Med 1992;176:261-4.
125. Salzman AL, Menconi MJ, Unno N, Ezzel RM, Casey DM, Gonzalez PK, et al. Nitric oxide dilates tight junctions and depletes ATP in cultured Caco-2BB intestinal epithelial monolayers. Am J Physiol 1995;268:G361-73.
126. Florquin S, Amraoui Z, Dubois C, Decuyper J, Goldman M. The protective role of endogenously synthesized nitric oxide in staphylococcal enterotoxin B-induced shock in mice. J Exp Med 1994;180:1153-8.
127. Stipanuk MH, Beck PW. Characterization of the enzymic capacity for cysteine desulphhydration in liver and kidney of the rat. Biochem J 1982;206:267-77.
128. Wang R. Two's company, three's a crowd: can H2S be the third endogenous gaseous transmitter? FASEB J 2002;16:1792-8.
129. Kimura H. Hydrogen sulfide as a neuromodulator. Mol Neurobiol 2002;26:13-9.
130. Wang R. The gasotransmitter role of hydrogen sulfide. Antioxid Redox Signal 2003;5:493-501.
131. Abe K, Kimura H. The possible role of hydrogen sulfide as an endogenous neuromodulator. J Neurosci 1996;16:1066-71.
132. Weimin Z, Jing Z, Yanjie L, Rui W. The vasorelaxant effect of H2S as a novel endogenous gaseous KATP channel opener. EMBO J 2001;20:6008-16.
133. Moore PK, Bhatia M, Moochhala S. Hydrogen sulfide: from the smell of the past to the mediator of the future? Trends Pharmacol Sci 2003;24:609-11.
134. Ling L, Bhatia M, Yizhun Z, Yichun Z, Raina DR, ZhongJing W, et al. Hydrogen sulfide is a novel mediator of lipopolysaccharide-induced inflammation in the mouse. FASEB J 2005;19:1196-8.
135. Collin M, Farhana BMA, Murch O, Bhatia M, Moore PK, Thiemermann C. Inhibition of endogenous hydrogen sulfide formation reduces the organ injury caused by endotoxemia. Br J Pharmacol 2005;146:498-505.
136. Yan H, Junbao D, Chaoshu T, Geng B, Hongfeng J. Changes in arterial hydrogen sulfide (H2S) content during septic shock and endotoxin shock in rats. J Infect 2003;47:155-60.
137. Bhatia M, Sidhapuriwala J, Moochhala SM, Moore PK. Hydrogen sulphide is a mediator of carrageenan-induced hindpaw oedema in the rat. Br J Pharmacol 2005;145:141-4.
138. Bhatia M, Wong FL, Fu D, Law HY, Moochhala SM, Moore PK. Role of hydrogen sulfide in acute pancreatitis and associated lung injury. FASEB J 2005;19:623-5.
139. Bin G, Jinghui Y, Yongfen Q, Jing Z, Yongzheng P, Junbao D, et al. H2S generated by heart in rat and its effects on cardiac function. Biochem Biophys Res Commun 2004;313:362-8.
140. Bin G, Lin C, Chunshui P, Yongfen Q, Jing Z, Yongzheng P, et al. Endogenous hydrogen sulfide regulation of myocardial injury induced by isoproterenol. Biochem Biophys Res Commun 2004;318:756-63.
141. Chunyu Z, Junbao D, Dingfang B, Hui Y, Xiuying T, Chaoshu T. The regulatory effect of hydrogen sulfide on hypoxic pulmonary hypertension in rats. Biochem Biophys Res Commun 2003;302:810-6.